Back

Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Smaller trials: cardiac function and remodelling Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Calvin Chin

National Heart Centre Singapore, Singapore (Singapore)

4 More presentations in this session

Presentation thumbnail
Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI)
Professor T. Marwick (Melbourne, AU)
Slides Video
Presentation thumbnail
Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial
Associate Professor S. Prabhu (Melbourne, AU)
Slides Video
Presentation thumbnail
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction
Doctor J. Carberry (Glasgow, GB)
Slides Video
Presentation thumbnail
Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.
Doctor Y. Hsu (Tainan, TW)
Slides Video

Access the full session

Session thumbnail
Smaller trials: cardiac function and remodelling
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Magnetic resonance imaging is the way to go for risk assessment
thumbnail
Congress Presentation
Cardiac magnetic resonance imaging in the work-up and management of cardiac amyloidosis
thumbnail
Congress Presentation
CMR for inflammation, oedema, and the pericardium

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources